MedTech Terms
    The authoritative reference
    All terms

    Safer Technologies Program

    FDA program for devices addressing less serious conditions but offering meaningful safety improvements.

    Reviewed by Christian Espinosa, Founder, Blue Goat CyberLast reviewed May 5, 2026

    Definition

    STeP provides Breakthrough-style benefits - interactive review and prioritization - for devices reasonably expected to significantly improve the safety of currently available treatments or diagnostics for non-life-threatening conditions.
    What the regulation says
    The Safer Technologies Program (STeP) was established by the FDA as a voluntary program to facilitate the development and expedite the review of certain medical devices that are reasonably expected to significantly improve the safety of currently available treatments or diagnostics. It operates similarly to the Breakthrough Devices Program, offering manufacturers opportunities for early and frequent engagement with FDA reviewers, as outlined in FDA guidance documents on the program. Devices eligible for STeP address non-life-threatening diseases or conditions and represent a safety improvement over existing alternatives, rather than a clinical effectiveness improvement.

    What this means in practice

    Often used for safer redesigns of existing devices (e.g., reducing infection risk, eliminating a hazardous material). Acceptance is selective.

    Examples

    • A novel catheter designed with an antimicrobial coating to significantly reduce the risk of hospital-acquired infections in routine, non-life-threatening procedures could be a candidate for STeP.
    • A redesigned infusion pump that incorporates advanced error-prevention technology to drastically lower medication administration errors for non-critical care patients might qualify for STeP.
    • A new material used in a medical implant for a non-life-threatening condition that eliminates the risk of a known biocompatibility issue present in existing materials could be considered for STeP.
    Common pitfalls
    • A common pitfall is misunderstanding that STeP focuses on safety improvements for non-life-threatening conditions, not efficacy for life-threatening ones. Another mistake is assuming all safety improvements qualify, as the program specifically targets "significant" safety improvements. Manufacturers sometimes fail to provide sufficient justification that their device offers a substantial safety improvement over existing technologies when applying for STeP designation.
    • Failing to engage with the FDA early and often, which is a key benefit of the STeP program, can hinder the expedited review process.
    • Misinterpreting "non-life-threatening conditions" can lead to inappropriate applications, as the program has specific criteria for this aspect.

    Frequently asked questions

    The primary goal of STeP is to enhance patient safety by expediting the development and review of devices that offer significant safety improvements for non-life-threatening conditions.
    Grouped by theme

    Mentioned in recent activity

    8 entries

    Latest in MedTech

    View all

    Recent regulatory actions, publications, and trials matched to this term. Updated daily.

    Primary references

    3 sources
    Link health: 3 verified· last checked 2026-06-20
    FDA·2European Commission·1
    1. 1
      Safer Technologies Program (STeP)
      Verified
      FDAfda.gov
    2. 2
      FDA - Medical Devices
      Verified
      FDAfda.gov
    3. 3
      European Commission - Medical Devices
      Verified
      European Commissionhealth.ec.europa.eu

    Inline markers like [1] jump to the matching reference above.